Applied Therapeutics (APLT) Stock Statistics & Valuation Metrics

Applied Therapeutics has a market cap or net worth of $62.29M. The enterprise value is $17.32M.

Applied Therapeutics has 141,575,530 shares outstanding. The number of shares has decreased by -2.65% in one year.

Applied Therapeutics’s return on equity (ROE) is -1.85 and return on invested capital (ROIC) is -173.23%.

The current PE Ratio of Applied Therapeutics is ―. Applied Therapeutics’s PEG ratio is ―.

In the last 12 months, Applied Therapeutics had revenue of 455.00K and earned -105.62M in profits. Earnings per share was -0.76.

In the last 12 months, operating cash flow was -91.78M and capital expenditures 0.00, giving a free cash flow of -91.78M billion.

Applied Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Applied Therapeutics upcoming earnings date is Nov 6, 2025, TBA (Confirmed).

Applied Therapeutics as a current ratio of 3.06, with Debt / Equity ratio of 14.92%

In the past 12 months, Applied Therapeutics has paid 0.00 in taxes.

Applied Therapeutics EV to EBITDA ratio is -0.41, with an EV/FCF ratio of -0.51.

Applied Therapeutics has $30.42M in cash and marketable securities with $2.60M in debt, giving a net cash position of -$27.82M billion.

Gross margin is -50.82%, with operating margin of -22922.86%, and net profit margin of -23214.07%.

The average price target for Applied Therapeutics is $2.25, which is 11.43% higher than the current price. The consensus rating is Moderate Buy